EUCAST Technical Note on Voriconazole and Aspergillus spp.

Clinical Microbiology and Infection

Volumn 19, Issue 6, 2013, Pages

  Hope, W W ^a   Cuenca Estrella, M ^b   Lass Florl C ^c   Arendrup, M C ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

Amphotericin; Aspergillus; Breakpoints; EUCAST Technical Note; Itraconazole; Posaconazole; Susceptibility testing

Indexed keywords

VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS; CANDIDIASIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG MONITORING; HUMAN; INVASIVE ASPERGILLOSIS; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MORTALITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ASPERGILLUS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 84876800912     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12148     Document Type: Article

References (11)

1. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010; 18: 195-204.
2. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee forAntimicrobial Susceptibility Testing (EUCAST). EUCAST Technical Note on voriconazole. Clin Microbiol Infect 2008; 14: 985-987.
3. Driscoll TA, Yu LC, Frangoul H et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother 2011; 55: 5770-5779.
4. Driscoll TA, Frangoul H, Nemecek ER et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob Agents Chemother 2011; 55: 5780-5789.
5. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50: 27-36.
6. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
7. Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother 2012; 56: 526-531.
8. Jeans AR, Howard SJ, Al-Nakeeb Z et al. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. J Infect Dis 2012; 206: 442-452.
9. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 2010; 54: 4758-4764.
10. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
11. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.